Universitätsklinikum Ulm

Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011)) (2021) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article, Erratum Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling (2020) Oberbeck S, Schrader A, Warner K, Jungherz D, Crispatzu G, Von Jan J, Chmielewski M, et al. Journal article Incidence of Secondary Malignancies After TBI/VP16 Conditioning for Childhood All - Results of the Prospective ALL-SCT-BFM-2003 Trial (2020) Eichinger A, Glogova E, Beier R, Guengoer T, Stachel D, Stachel D, Lang P, et al. Conference contribution Reaming of femoral fractures with different reaming irrigator aspirator systems shows distinct effects on cardiac function after experimental polytrauma (2020) Lackner I, Weber B, Miclau T, Holzwarth N, Baur M, Gebhard F, Teuben M, et al. Journal article Systemic and Cardiac Alterations After Long Bone Fracture (2020) Weber B, Lackner I, Knecht D, Braun CK, Gebhard F, Huber-Lang M, Hildebrand F, et al. Journal article The health-related quality of life of sarcoma patients and survivors in germany—cross-sectional results of a nationwide observational study (Prosa) (2020) Eichler M, Hentschel L, Richter S, Hohenberger P, Kasper B, Andreou D, Pink D, et al. Journal article Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany (2020) Hübner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Journal article Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial (2020) de Gregorio A, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, et al. Journal article Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany (2020) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC (2020) Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, et al. Journal article